Literature DB >> 1851890

Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study.

D G McLeod1, R B Weiss, D M Stablein, F M Muggia, D F Paulson, J H Ellis, J T Spaulding, J P Donohue.   

Abstract

The Testicular Cancer Center Intergroup Study entered surgically staged patients with nonseminomatous tumor and metastases limited to the regional lymph nodes into a previously reported cooperative trial of immediate versus delayed therapy for positive retroperitoneal node disease. Patients with negative nodes (stage I) were placed in an observation registry with specified treatment strategy upon relapse. Of 264 stage I cancer patients 27 (10.2%) had recurrence: 5 of these 27 patients died after recurrence of the testicular malignancies, while 4 other nontumor-related deaths have occurred. Pre-lymphadenectomy staging characteristics observed to predict significantly node positivity are the results of radiological examinations, presence of tumor invasion, vascular invasion and tumor histology. In a multiple logistic regression analysis with these variables, misclassification still occurs in more than a fourth of the patients. Future refinements in diagnosis may allow for better prediction of these patients at risk to have positive lymph nodes and ultimately recurrence. Presently, if assessment of nodal involvement is the objective, noninvasive procedures are not an adequate substitute for surgical staging with modified lymphadenectomy.

Entities:  

Mesh:

Year:  1991        PMID: 1851890     DOI: 10.1016/s0022-5347(17)38567-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 3.  Optimal drug therapy in the treatment of testicular cancer.

Authors:  E R Priest; N J Vogelzang
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 4.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 5.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 6.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

7.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

8.  Efficacy of routine follow-up after first-line treatment for testicular cancer.

Authors:  J R Spermon; J A Witjes; L A L M Kiemeney
Journal:  World J Urol       Date:  2004-09-21       Impact factor: 4.226

9.  Fusion imaging: a novel staging modality in testis cancer.

Authors:  Joseph R Sterbis; Kevin R Rice; Marcia C Javitt; Noah S Schenkman; Stephen A Brassell
Journal:  J Cancer       Date:  2010-11-05       Impact factor: 4.207

Review 10.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.

Authors:  P D Humphries; I Zerizer
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.